For the millions of adults now prescribed GLP-1 receptor agonists and dual incretin therapies, the drug itself may be only half the equation. Emerging clinical guidance suggests that how patients eat, move, and manage side effects while on these medications may meaningfully determine whether weight loss translates into durable metabolic health — or simply a temporary number on the scale.
This JAMA Insights piece addresses the intersection of behavioral strategies and pharmacological treatment in obesity management, specifically for patients using incretin-based agents such as semaglutide and tirzepatide. The discussion centers on optimizing lifestyle modifications — including dietary quality, physical activity patterns, and protein intake — to complement the appetite-suppressing and glucoregulatory effects of these drugs. It also examines clinical approaches to managing the gastrointestinal adverse effects that frequently lead to dose reduction or discontinuation, including nausea, vomiting, and constipation, which remain the most common barriers to therapeutic adherence.
The incretin drug class has generated extraordinary momentum since semaglutide's approval for obesity, with tirzepatide now achieving 20–22% mean body weight reductions in trials — figures previously associated only with bariatric surgery. Yet a critical gap in the literature concerns what happens at the behavioral level while patients are medicated. Muscle mass preservation is a particular concern; studies suggest that roughly 25–39% of weight lost on GLP-1 therapies may come from lean tissue rather than fat alone, making resistance training and adequate dietary protein not optional additions but clinical priorities. The practical limitation of this JAMA piece is its Insights format — broad guidance rather than primary data — meaning clinicians and patients should treat it as a framework, not a protocol. Still, its publication in JAMA signals growing consensus that prescribing an incretin without a structured lifestyle plan may represent an incomplete standard of care.
